Navigation Links
MedImmune Highlights Inflammatory Disease Portfolio at 73rd Annual Meeting of the American College of Rheumatology
Date:10/15/2009

GAITHERSBURG, Md., Oct. 15 /PRNewswire/ -- MedImmune today announced that researchers will present data on several inflammatory disease programs at the annual meeting of the American College of Rheumatology, from October 17 to 21, 2009 at the Pennsylvania Convention Center in Philadelphia, Pennsylvania.

"Through our research into novel disease pathways involved in autoimmune disorders, we continue to fulfill our mission of using scientific excellence to deliver life-changing medicines for patients with rheumatic diseases," said Anthony Coyle, PhD., vice president, head of respiratory, inflammation, and autoimmune disease research. "Representing some of our most recent progress, we are pleased to share data relevant to the development of new therapies for conditions such as lupus, rheumatoid arthritis, and scleroderma."

The schedule for MedImmune's nine posters and two oral presentations at the meeting, starting on Saturday October 17, is as follows:

  • Relationship Between Disease Activity and Type 1 Interferon- and Other Cytokine-Inducible Gene Expression in Blood in Dermatomyositis and Polymyositis (Oral Presentation)-Steven Greeberg, Ph.D., Sunday, October 18 at 3:00 p.m. in Room 202 B
  • In Vitro and In Vivo Properties of MEDI-571, a Human Anti IL-17A Antibody in Development for the Treatment of Patients with Rheumatoid Arthritis - Matthew Sleeman, Ph.D., Sunday, October 18 from 9:00 a.m. - 11:00 a.m. in Hall D, Abstract: 8
  • Utilising Assay Systems Relevant to IL-6 Mechanisms in Rheumatoid Arthritis to Demonstrate Efficacy of a Novel Human Anti-IL-6 Antibody, CAT6001 -Donna Finch, Ph.D., Sunday, October 18 from 9:00 a.m. - 11:00 a.m. in Hall D, Abstract: 45, Abstract: 587
  • MEDI5117: A Human High Affinity Anti-IL-6 Monoclonal Antibody with Enhanced Serum Half-Life in Development for the Treatment of Inflammation and Rheumatological Diseases - Jacques Moisan, Ph.D., Sunday, October 18 from 9:00 a.m. - 11:00 a.m. in Hall D, Abstract: 401
  • Tissue Plasminogen Activator (tPA) Restores Normal Fibrinolysis / Coagulation Balance in Kidney and Reverses Clinical Score in Skin in a Murine Graft-Versus-Host Disease Model of Scleroderma: Proof of Concept for Therapeutic Fibrinolysis in Scleroderma - Timothy Burwell, B.Sc., Monday, October 19 from 9:00 a.m. - 11:00 a.m. in Hall D, Abstract: 1062
  • Neutralization of Angiopoietin 2 Reduces Disease in Murine Arthritis and Augments Efficacy of Anti-TNF Treatment - Brian Naiman, MS., Monday, October 19 from 9:00 a.m. - 11:00 a.m. in Hall D, Abstract: 666
  • Critical Requirement of RAGE for Development of Lung Fibrosis in An Experimental Model of Systemic Sclerosis -Tracy Delaney, M.Sc., Monday, October 19 from 9:00 a.m. - 11:00 a.m. in Hall D, Abstract: 1053
  • Depletion of Inducible Co-Stimulator (ICOS) Bearing T Cells Inhibits Expansion of T Follicular Helper Cells (TFH) and Prevents Disease in a Graft Versus Host Mouse Model of Scleroderma - Gianluca Carlesso, Ph.D., Monday, October 19 from 9:00 a.m. - 11:00 a.m. in Hall D, Abstract: 1065
  • Autoimmune-Driven Skin Fibrosis: The Critical Requirement for IFNAR1 in An Experimental Model of Systemic Sclerosis - Tracy Delaney, M.Sc., Monday, October 19 from 9:00 a.m. - 11:00 a.m. in Hall D, Abstract: 1067
  • Human S100 Proteins Differentially Regulate Pro-Inflammatory Cytokine Release and Cell Migration - Bo Chen, Ph.D., Tuesday, October 20 from 9:00 a.m. - 11:00 a.m. in Hall D, Abstract: 1331
  • CAM-3001; a Novel Human Monoclonal Antibody against GM-CSFR-a, in Subjects with Rheumatoid Arthritis (RA): Results of a Phi Study (Oral Presentation) - Gerd-R Burmester, M.D., Monday, October 19 from 9:00 a.m. - 11:00 a.m. in Hall D, Abstract: 1926

About MedImmune

MedImmune, the worldwide biologics business for AstraZeneca PLC (LSE: AZN.L, NYSE: AZN), has approximately 3,300 employees worldwide and is headquartered in Gaithersburg, Maryland. With an advancing pipeline of promising candidates, we aim to be the next revolutionary force in biotechnology by delivering life-changing products, industry-leading performance, and a tireless commitment to improving patient health. For more information, visit MedImmune's website at www.medimmune.com.

SOURCE MedImmune


'/>"/>
SOURCE MedImmune
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Rib-X Pharmaceuticals, Inc. Appoints Tony Zook of MedImmune to Board of Directors
2. HHS Awards MedImmune Contract to Manufacture Live Attenuated Nasal Spray Vaccine for Novel Influenza A (H1N1)
3. MedImmune Advances Asthma Program With Start of Phase 2 Clinical Trial for Antibody Targeting IL-5 Receptor
4. MedImmune Announces Zook as President
5. MedImmune Presents Data Highlighting its Progressive Inflammatory Disease Portfolio at the 72nd Annual Meeting of the American College of Rheumatology
6. MedImmune Licenses Reverse Genetics Technology to Hungarys Omninvest for Use in Influenza Vaccine Development and Production
7. MedImmune Expands R&D Capacity with New Research Facility in Cambridge, U.K.
8. MedImmune Presents Data at AAP National Conference & Exhibition Demonstrating Burden of RSV Disease
9. Pinnacle Biologics Announces Stock Purchase Agreement With MedImmune
10. MedImmunes Brian Rosen Honored by Montgomery County Chamber at 49th Annual Awards Dinner
11. Depth of MedImmunes Respiratory Disease Research Program Highlighted at Annual Meeting of the American Thoracic Society
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... 24, 2016  Regular discussions on a range of subjects ... the two entities said Poloz. Speaking at a ... , he pointed to the country,s inflation target, which ... "In certain areas ... have common economic goals, why not sit down and address ...
(Date:6/24/2016)... ... ... Researchers at the Universita Politecnica delle Marche in Ancona combed medical journal ... Their findings are the subject of a new article on the Surviving Mesothelioma website. ... the blood, lung fluid or tissue of mesothelioma patients that can help point doctors ...
(Date:6/23/2016)... June 23, 2016   Boston Biomedical , ... compounds designed to target cancer stemness pathways, announced ... granted Orphan Drug Designation from the U.S. Food ... gastric cancer, including gastroesophageal junction (GEJ) cancer. Napabucasin ... to inhibit cancer stemness pathways by targeting STAT3, ...
(Date:6/23/2016)... 2016 Houston Methodist Willowbrook Hospital has ... Association to serve as their official health care ... Willowbrook will provide sponsorship support, athletic training services, ... coaches, volunteers, athletes and families. "We ... Association and to bring Houston Methodist quality services ...
Breaking Biology Technology:
(Date:5/16/2016)... , May 16, 2016   EyeLock LLC ... today announced the opening of an IoT Center of ... strengthen and expand the development of embedded iris biometric ... unprecedented level of convenience and security with unmatched biometric ... one,s identity aside from DNA. EyeLock,s platform uses video ...
(Date:5/3/2016)... Lithuania , May 3, 2016  Neurotechnology, ... released the MegaMatcher Automated Biometric Identification System ... of large-scale multi-biometric projects. MegaMatcher ABIS can process ... accuracy using any combination of fingerprint, face or ... MegaMatcher SDK and MegaMatcher Accelerator ...
(Date:4/26/2016)... and LONDON , ... Finacle, part of EdgeVerve Systems, a product subsidiary ... Onegini today announced a partnership to integrate the ...      (Logo: http://photos.prnewswire.com/prnh/20151104/283829LOGO ) ... provide their customers enhanced security to access and ...
Breaking Biology News(10 mins):